Neoadjuvant and adjuvant chemohormonotherapy in patients with prostate cancer with high risk for progression


DOI: https://dx.doi.org/10.18565/pharmateca.2019.12.86-91

T.V. Ustinova (1), L.V. Bolotina (1), N.V. Kharchenko (2), A.A. Paichadze (1), B.Ya. Alekseev (1), A.L. Kornietskaya (1), K.M. Isaeva (3), A.A. Kachmazov (1), A.D. Kaprin (1), A.A. Fedenko (1)

1) P.A. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiology Center, Moscow, Russia; 2) Peoples’ Friendship University of Russia, Moscow, Russia; 3) Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Prostate cancer (PC) is an actual disease and a frequent oncological pathology in men. The detection rate of locally advanced and lymphogenic disseminated forms of prostate cancer in Russia remains high. Therapeutic tactics in PC patients is determined by the prevalence of the tumor process, the stage of the disease, and belonging to a risk group. In patients with a high and extremely high risk of disease progression, a multimodal approach can be considered. To date, there are many studies on neoadjuvant therapy, and there are also a number of works on adjuvant drug treatment. Neoadjuvant chemohormonotherapy at the first stage as part of a conditionally combined treatment demonstrates the advantage of this approach. Regarding the use of adjuvant chemotherapy, the data are contradictory. Further research is required to understand the appropriateness of this treatment approach. In the near future, probably, a multimodal approach to the treatment of patients of this cohort will be included in the standards of antitumor therapy.
Keywords: prostate cancer with high risk for progression, neoadjuvant chemohormonotherapy, adjuvant chemohormonotherapy, multimodal approach

About the Autors


Corresponding author: Larissa V. Bolotina, MD, Head of the Department of Chemotherapy, Division of Drug Treatment of Tumors, National Medical Research Radiology Center, Moscow, Russia; e-mail: lbolotina@yandex.ru
Address: 3, 2nd Botkinsky passage, Moscow 125284, Russian Federation


Бионика Медиа